CN112402584A - 一种用于治疗骨关节炎的中西药复方药物及其制备方法 - Google Patents
一种用于治疗骨关节炎的中西药复方药物及其制备方法 Download PDFInfo
- Publication number
- CN112402584A CN112402584A CN201910781863.XA CN201910781863A CN112402584A CN 112402584 A CN112402584 A CN 112402584A CN 201910781863 A CN201910781863 A CN 201910781863A CN 112402584 A CN112402584 A CN 112402584A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- raw material
- chinese
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 169
- 201000008482 osteoarthritis Diseases 0.000 title claims abstract description 60
- 150000001875 compounds Chemical class 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 30
- 229910052802 copper Inorganic materials 0.000 claims abstract description 30
- 239000010949 copper Substances 0.000 claims abstract description 30
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 22
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 claims abstract description 18
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960002442 glucosamine Drugs 0.000 claims abstract description 18
- 102000008186 Collagen Human genes 0.000 claims abstract description 14
- 108010035532 Collagen Proteins 0.000 claims abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 14
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 14
- 229920001436 collagen Polymers 0.000 claims abstract description 14
- 229960002702 piroxicam Drugs 0.000 claims abstract description 14
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims abstract description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 241001061264 Astragalus Species 0.000 claims abstract description 13
- 241000893536 Epimedium Species 0.000 claims abstract description 13
- 240000005779 Jasminum multiflorum Species 0.000 claims abstract description 13
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 13
- 235000006533 astragalus Nutrition 0.000 claims abstract description 13
- 235000018905 epimedium Nutrition 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 210000004233 talus Anatomy 0.000 claims abstract description 13
- 241000241550 Cyathula Species 0.000 claims abstract description 11
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 4
- 229940079593 drug Drugs 0.000 claims description 50
- 239000002245 particle Substances 0.000 claims description 50
- 239000002994 raw material Substances 0.000 claims description 47
- 238000002156 mixing Methods 0.000 claims description 44
- 239000006228 supernatant Substances 0.000 claims description 42
- 239000000284 extract Substances 0.000 claims description 37
- 239000008213 purified water Substances 0.000 claims description 24
- 239000013049 sediment Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 238000005303 weighing Methods 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 16
- 230000002829 reductive effect Effects 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- 238000004140 cleaning Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- 238000000643 oven drying Methods 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000002699 waste material Substances 0.000 claims description 2
- 229940126678 chinese medicines Drugs 0.000 abstract 1
- 229940126673 western medicines Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 24
- 208000002193 Pain Diseases 0.000 description 22
- 230000036407 pain Effects 0.000 description 21
- 238000011282 treatment Methods 0.000 description 17
- 206010042674 Swelling Diseases 0.000 description 10
- 230000008961 swelling Effects 0.000 description 10
- 208000006820 Arthralgia Diseases 0.000 description 9
- 244000132619 red sage Species 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 210000000629 knee joint Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 206010005963 Bone formation increased Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 2
- 206010072970 Meniscus injury Diseases 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000037182 bone density Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000004353 tibial menisci Anatomy 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008414 cartilage metabolism Effects 0.000 description 1
- 239000003042 chondroprotective agent Substances 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 210000004439 collateral ligament Anatomy 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000009427 jiangzhi Substances 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000013187 longer-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000011085 pressure filtration Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000005065 subchondral bone plate Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供一种用于治疗骨关节炎的中西药复方药物,由中药成分和西药成分组成,中药成分包括络石藤、丹参、黄芪、甘草、自然铜、淫羊藿、川牛膝,西药成分包括氨基葡萄糖、耗牛骨胶原蛋白肽、吡罗昔康、氢氧化铝,本发明有机结合天然中草药与西药,调整中西药的配伍性、适用性,制备用于治疗骨关节炎的中西药复方药物,通过改善微循环,促进血流速,消肿止痛,在快速治疗骨关节炎的同时,增加骨密度,保护胃黏膜,避免副反应发生,患者适用性好,从根本上提升轻度、中度、重度骨关节炎患者的治愈效果。
Description
技术领域
本发明涉及医药技术领域,具体涉及一种用于治疗骨关节炎的中西药复方药物。
背景技术
骨关节炎(osteoarthritis,OA)又称为骨关节病,退行性关节病和骨质增生,是一种最常见的关节疾病。该病不仅发生关节软骨损害,还累及整个关节,包括软骨下骨、韧带、关节囊、滑膜和关节周围肌肉,最终发生关节软骨退变、纤维化、断裂、溃疡及整个关节面的损害。典型的临床表现包括疼痛,僵硬和关节变形。药物和手术是解决骨关节炎最主要的方法,一般在患病之后,患者都愿意采用药物进行控制治疗,即便是采用手术,骨关节炎的药物治疗也是必不可少的,因此大致了解能够治疗骨关节炎的药物也是很有必要的,有利于病情的恢复。
目前治疗骨关节炎的口服药物包括以下几种:
①抗炎止痛药:国外首选对乙酰氨基酚,该药物止痛效果好,不良反应少,费用低。通常1日总量不超过3g,但长期大剂量使用有引起肝或肾损伤的报告。如果此类药物止痛效果不明显或伴有膝关节积液,宜选用其他药物。
②非甾体类抗炎药:这类药物具有抗炎、止痛和解热作用,是治疗骨关节炎最常用的药物。但是其中有的阿司匹林、水杨酸、保泰松、吲哚美辛和萘普生等,对关节软骨基质蛋白聚糖合成有抑制作用,不利于骨关节炎,不宜选用,至少不应长期使用。另一些药物如双氯芬酸、吡罗昔康、萘丁美酮、依托度酸、舒林酸和阿西美辛等,通过抑制环氧合酶使组织局部前列腺素的合成减少,抑制白细胞的趋化性和溶酶体酶的释放而发挥药理作用,对心血管和肾的不良影响少。这类药物在骨关节炎的保守治疗中必不可缺,但是有较严重的并发症(胃肠道损伤如穿孔、溃疡或出血等)。
③阿片类:对中度至严重的膝骨关节炎患者,以上药物治疗仍不能解除疼痛时,国外学者主张将阿片类药物作为最后选择。经常选用的这类药物有可待因和曲马多。有一定的效果,但是,该类药物的不良反应如恶心、呕吐、腹泻和多汗,以及有一定的耐受性和潜在的依赖性都值得重视。
④氨基葡萄糖:抗炎药只能解除或减轻骨关节炎的症状,不能改变其病变发展。为此,多年来人们都在探索控制骨关节炎发展的改变病情的药物。氨基葡萄糖既能抗炎止痛,又有延缓膝骨关节炎发展的作用,被认为是第一个改变骨关节炎病情的药物或慢作用药,体外实验也证实其对软骨代谢有良好作用,也称其为软骨保护剂。长期使用氨基葡萄糖治疗可阻止膝关节骨关节炎的发展。在美国,氨基葡萄糖是营养品,在超市即可购得。在欧洲及其他地区,它是处方药。近几年,它在我国逐渐受到临床医师和患者的重视。如能把握时机,在骨关节炎早期开始并坚持较长期的治疗,可能会有教好的效果。
药物能够很好的控制骨关节炎,但是正确使用药物是治疗的关键。但是不同药物的副作用不同、治疗效果不一,目前尚无一种药物可以使骨关节炎的病程逆转和停止,因此需要开发副作用小、治疗效果好、具有良好的普适性的骨关节炎药物,从根本上医治骨关节炎患者。
发明内容
本发明为解决现有技术中骨关节炎药物配方复杂、副作用大、治疗周期长,对于重症患者治疗效果不明显、患者需要后期手术等问题,提供了一种用于治疗骨关节炎的中西药复方药物,疗效好、配方简单,适于批量化生产。
一种用于治疗骨关节炎的中西药复方药物,是由中药成分和西药成分组成,所述中药成分主要是由以下重量份原料药提取制备而成:络石藤15.80-17.40份、丹参18.62-22.15份、黄芪17.56-20.16份、甘草6.4-10.02份、自然铜9.52-13.26份、淫羊藿11.16-14.61份、川牛膝8.26-12.33份,所述西药成分主要是由以下重量份原料药混合而成:氨基葡萄糖0.50-0.55份、耗牛骨胶原蛋白肽0.38-0.44份、吡罗昔康0-0.04份、氢氧化铝0.37-0.47份。
所述的一种用于治疗骨关节炎的中西药复方药物,所述中药成分主要是由以下重量份原料药提取制备而成:络石藤16.44份、丹参20.55份、黄芪18.50份、甘草8.22份、自然铜12.33份、淫羊藿12.33份、川牛膝10.28份,所述西药成分主要是由以下重量份原料药混合而成:氨基葡萄糖0.51份、耗牛骨胶原蛋白肽0.41份、吡罗昔康0.02份、氢氧化铝0.41份。
一种用于治疗骨关节炎的中西药复方药物的制备方法,其特征在于,包括以下步骤:
(1)按重量份比例称取络石藤、丹参、黄芪、甘草、淫羊藿、川牛膝原料药,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7-8倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在3000-5500r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.15-0.18MPa、真空度720-780mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取自然铜原料药,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.15-0.18MPa、真空度720-780mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取氨基葡萄糖、耗牛骨胶原蛋白肽、吡罗昔康、氢氧化铝原料药,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至60-80℃,烘干,制成粒度为20-80目的颗粒,按照3.2-3.5g/每袋的规格装袋。
其中中药、西药成分的药理作用为:
络石藤:性微寒,味苦。祛风通络,凉血消肿。用于风湿热痹、筋脉拘挛、腰膝酸痛、喉痹、痈肿、跌扑损伤。
丹参:性味苦,微寒。祛瘀止痛,活血通经,清心除烦。用于月经不调,经闭痛经,症瘕积聚,胸腹刺痛,热痹疼痛,疮疡肿痛,心烦不眠;肝脾肿大,心绞痛。
黄芪:性味:甘,微温。有增强机体免疫功能、保肝、利尿、抗衰老、抗应激、降压和较广泛的抗菌作用。
甘草:性味甘,平。补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
淫羊藿:味辛甘性温。增加心脑血管血流量,促进造血功能、免疫功能及骨代谢,具有抗衰老、抗肿瘤等功效。
川牛膝:性味甘、微苦,平。逐瘀通经,通利关节,利尿通淋。用于经闭症瘕,胞衣不下,关节痹痛,足痿筋挛,尿血血淋,跌扑损伤。
自然铜:性味辛,平。散瘀,接骨,止痛。用于跌扑肿痛,筋骨折伤。
氨基葡萄糖:缓解和消除骨性关节炎的疼痛、肿胀等症状,改善关节活动功能。
耗牛骨胶原蛋白肽:从牦牛提取有效的类骨胶原物质因子,以及天然而新鲜的骨钙等微量元素,补钙和养骨双管齐下,促进骨伤愈合、预防骨质疏松、关节疼痛、骨酸骨痛,效果更显著。
吡罗昔康:通过抑制环氧合酶使组织局部前列腺素的合成减少,抑制白细胞的趋化性和溶酶体酶的释放而发挥药理作用,用于用于治疗风湿性及类风湿性关节炎,有明显的镇痛、抗炎及一定的消肿作用。
氢氧化铝:胃粘膜保护剂,防止药物刺激骨粘膜造成伤害,防止胃出血等。
本发明的有益效果是:
1、本发明有机结合天然中草药与西药,调整中西药的配伍性、适用性,制备用于治疗骨关节炎的中西药复方药物,通过改善微循环,促进血流速,消肿止痛,在快速治疗骨关节炎的同时,增加骨密度,保护胃黏膜,避免副反应发生,从根本上提升轻度、中度、重度骨关节炎患者的治愈效果;
2、本发明的治疗骨关节炎的中西药复方药物配方中均为中药和非激素西药,治疗效果好,无不良反应发生,患者对本发明药物的普适性好。
具体实施方式:
下面结合具体实施例对本发明进行更进一步详细的说明。
实施例1:
(1)按重量份比例称取原料药络石藤16.44份、丹参20.55份、黄芪18.50份、甘草8.22份、淫羊藿12.33份、川牛膝10.28份,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7.6倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在3000r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.16MPa、真空度750mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取原料药自然铜12.33份,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.16MPa、真空度760mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取原料药氨基葡萄糖0.51份、耗牛骨胶原蛋白肽0.41份、吡罗昔康0.02份、氢氧化铝0.41份,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至60℃,烘干,制成粒度为20-80目的颗粒,按照3.2g/每袋的规格装袋,得到治疗骨关节炎的中西药复方药物1。
实施例2:
(1)按重量份比例称取原料药络石藤17.40份、丹参22.15份、黄芪20.16份、甘草6.40份、淫羊藿14.61份、川牛膝8.26份,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与8倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在5500r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.18MPa、真空度760mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取原料药自然铜9.52份,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.18MPa、真空度760mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取原料药氨基葡萄糖0.55份、耗牛骨胶原蛋白肽0.44份、吡罗昔康0.04份、氢氧化铝0.47份,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至80℃,烘干,制成粒度为20-80目的颗粒,按照3.2g/每袋的规格装袋,得到治疗骨关节炎的中西药复方药物2。
实施例3:
(1)按重量份比例称取原料药络石藤15.8份、丹参18.62份、黄芪17.56份、甘草10.02份、淫羊藿11.16份、川牛膝12.33份,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在3500r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.17MPa、真空度780mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取原料药自然铜13.26份,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.16MPa、真空度780mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取原料药氨基葡萄糖0.50份、耗牛骨胶原蛋白肽0.38份、氢氧化铝0.37份,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至70℃,烘干,制成粒度为20-80目的颗粒,按照3.2g/每袋的规格装袋,得到治疗骨关节炎的中西药复方药物3。
实施例4:
(1)按重量份比例称取原料药络石藤16.52份、丹参19.48份、黄芪19.32份、甘草8.25份、淫羊藿14.35份、川牛膝10.33份,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7.8倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在4300r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.15MPa、真空度750mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取原料药自然铜10.42份,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.15MPa、真空度750mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取原料药氨基葡萄糖0.52份、耗牛骨胶原蛋白肽0.42份、吡罗昔康0.01份、氢氧化铝0.38份,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至64℃,烘干,制成粒度为20-80目的颗粒,按照3.2g/每袋的规格装袋,得到治疗骨关节炎的中西药复方药物4。
实施例5:
(1)按重量份比例称取原料药络石藤17.10份、丹参19.58份、黄芪17.92份、甘草7.60份、淫羊藿13.45份、川牛膝10.06份,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7.5倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在4800r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.17MPa、真空度770mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取原料药自然铜12.96份,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.17MPa、真空度770mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取原料药氨基葡萄糖0.53份、耗牛骨胶原蛋白肽0.40份、吡罗昔康0.01份、氢氧化铝0.39份,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至60-80℃,烘干,制成粒度为20-80目的颗粒,按照5-7g/每袋的规格装袋,得到治疗骨关节炎的中西药复方药物5。
实施例6:
(1)按重量份比例称取原料药络石藤16.49份、丹参20.44份、黄芪18.00份、甘草9.36份、淫羊藿12.52份、川牛膝9.85份,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7.3倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在5200r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.16MPa、真空度720mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取原料药自然铜11.98份,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.16MPa、真空度720mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取原料药氨基葡萄糖0.54份、耗牛骨胶原蛋白肽0.39份、吡罗昔康0.03份、氢氧化铝0.4份,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至75℃,烘干,制成粒度为20-80目的颗粒,按照3.2g/每袋的规格装袋,得到治疗骨关节炎的中西药复方药物6。
本发明的用于治疗骨关节炎的中西药复方药物服用方法,一天两次,每次服用6.4g,即服用3.2g/袋的药物2袋,早晚饭后半小时口服。
临床案例:
为表明本发明的用于治疗骨关节炎的中西药复方药物对风湿骨病的治疗效果,对218例病例进行临床观察,其中男性83人,女性135人,年龄25岁-79岁,病程15天-27年,212人治愈,治愈率达到97.25%,有效率达到100%。
张某,男,64岁,30年病史,2017年4月检查核磁共振结果为:左膝关节构成骨边缘骨质变尖,内侧半月板后角及外侧半月板信号不均,内外侧副韧带及交叉韧带连续。髌上囊、关节腔内见长T1、STIR高信号影,被诊断为关节退行性病变引发骨性关节炎,骨质增生,半月板损伤,关节腔积水,关节变形。使用实施例1制备的用于治疗骨关节炎的中西药复方药物1治疗,连续服用5天疼痛的情况明显减轻了,基本上走路问题不大,左右摇摆明显减轻,连续服药50天康复,随诊一年后无复发。
王某,女,30岁,五年病史的左踝关节外伤性关节炎,关节间隙变窄,医生建议做关节置换或者骨性融合手术。未做手术,使用实施例3制备的用于治疗骨关节炎的中西药复方药物3治疗,连续服用3天疼痛的情况明显减轻了,服药35天康复,随诊两年后无复发。
吴某,女,52岁,10年病史,关节疼痛,不能弯曲,上下楼梯发出响声,下蹲困难,被诊断为半月板损伤,骨关节炎,有胃病。使用实施例2制备的用于治疗骨关节炎的中西药复方药物2治疗,连续服用3天关节疼痛的情况明显减轻,服药50天康复,服药过程中无胃部不适发生,随诊两年后无复发。
姜某,男,70岁,15年病史,右面腰窝里的骨头疼有强制性关节炎病史,平躺疼,运动也疼,弯腰疼,有时候会影响走路。使用实施例1制备的用于治疗骨关节炎的中西药复方药物1治疗,连续服用8天关节疼痛的情况明显减轻,服药15天痛感消失,服药90天康复,随诊6个月后无复发。
王某,女,26岁,6年病史,膝关节经常痛,不痛的时候和平常人是一样的,关节外面无异样,没有肿胀,但血向超标。使用实施例4制备的用于治疗骨关节炎的中西药复方药物4治疗,连续服用3天关节疼痛的情况明显减轻,服药20天康复,随诊8个月后无复发。
本发明的用于治疗骨关节炎的中西药复方药物,通过改善微循环,促进血流速,消肿止痛,在快速治疗骨关节炎的同时,增加骨密度,保护胃黏膜,避免副反应发生,从根本上提升轻度、中度、重度骨关节炎患者的治愈效果,10-30年骨关节炎病史的患者连续服药50-90天可治愈,治疗效果显著,缩短治疗周期,提升治愈比例。
本发明中实施例仅用以说明本发明的技术方案,而非其限制,尽管参照前述实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解,对上述实施例所记载的技术方案进行简单修改或者等同替换形成的新的技术方案均匀本技术方案的实质相同。
Claims (3)
1.一种用于治疗骨关节炎的中西药复方药物,是由中药成分和西药成分组成,其特征在于,所述中药成分主要是由以下重量份原料药提取制备而成:络石藤15.80-17.40份、丹参18.62-22.15份、黄芪17.56-20.16份、甘草6.4-10.02份、自然铜9.52-13.26份、淫羊藿11.16-14.61份、川牛膝8.26-12.33份,所述西药成分主要是由以下重量份原料药混合而成:氨基葡萄糖0.50-0.55份、耗牛骨胶原蛋白肽0.38-0.44份、吡罗昔康0-0.04份、氢氧化铝0.37-0.47份。
2.根据权利要求1所述的一种用于治疗骨关节炎的中西药复方药物,其特征在于,所述中药成分主要是由以下重量份原料药提取制备而成:络石藤16.44份、丹参20.55份、黄芪18.50份、甘草8.22份、自然铜12.33份、淫羊藿12.33份、川牛膝10.28份,所述西药成分主要是由以下重量份原料药混合而成:氨基葡萄糖0.51份、耗牛骨胶原蛋白肽0.41份、吡罗昔康0.02份、氢氧化铝0.41份。
3.一种用于治疗骨关节炎的中西药复方药物的制备方法,其特征在于,包括以下步骤:
(1)按重量份比例称取络石藤、丹参、黄芪、甘草、淫羊藿、川牛膝原料药,原料药经清洗、晾干、粉碎至0.08mm粒度,得到原料药颗粒A,原料药颗粒A与7-8倍的纯化水混合煎煮4h后,静置2h,倒出上清液C,将剩余的沉渣颗粒B与4倍的纯化水混合煎煮2.5h,在3000-5500r/min的转速下离心,分离得到沉渣颗粒D和上清液E;将上清液C和上清液E混合,在蒸汽压力0.15-0.18MPa、真空度720-780mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏F,中药浸膏F的密度为1.08g/cm3;
(2)按重量份比例称取自然铜原料药,自然铜原料药经废碎至30-60目,加9倍的纯化水混合煎煮10h,静置1.5h,采用压滤方式将自然铜沉渣颗粒G与上清液H分离,上清液H在蒸汽压力0.15-0.18MPa、真空度720-780mmhg、温度75℃的条件下,采用真空减压浓缩成中药浸膏J,中药浸膏J的密度为1.08g/cm3;
(3)按重量份比例称取氨基葡萄糖、耗牛骨胶原蛋白肽、吡罗昔康、氢氧化铝原料药,研磨为100-150目细粉M;
(4)将中药浸膏F、中药浸膏J与细粉M混合,搅拌并加热至60-80℃,烘干,制成粒度为20-80目的颗粒,按照3.2-3.5g/每袋的规格装袋。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910781863.XA CN112402584A (zh) | 2019-08-23 | 2019-08-23 | 一种用于治疗骨关节炎的中西药复方药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910781863.XA CN112402584A (zh) | 2019-08-23 | 2019-08-23 | 一种用于治疗骨关节炎的中西药复方药物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112402584A true CN112402584A (zh) | 2021-02-26 |
Family
ID=74779384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910781863.XA Withdrawn CN112402584A (zh) | 2019-08-23 | 2019-08-23 | 一种用于治疗骨关节炎的中西药复方药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112402584A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113230381A (zh) * | 2021-06-01 | 2021-08-10 | 杭州丽昌农业科技有限公司 | 一种增加骨密度的配方 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1483452A (zh) * | 2003-07-21 | 2004-03-24 | 沈阳海慧科技投资有限公司 | 一种治疗风湿病及骨关节炎的中西药复方新药及其生产方法 |
CN104958520A (zh) * | 2015-07-25 | 2015-10-07 | 王璐 | 一种治疗骨性关节炎的中药 |
-
2019
- 2019-08-23 CN CN201910781863.XA patent/CN112402584A/zh not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1483452A (zh) * | 2003-07-21 | 2004-03-24 | 沈阳海慧科技投资有限公司 | 一种治疗风湿病及骨关节炎的中西药复方新药及其生产方法 |
CN104958520A (zh) * | 2015-07-25 | 2015-10-07 | 王璐 | 一种治疗骨性关节炎的中药 |
Non-Patent Citations (3)
Title |
---|
刘茵等: "氨基葡萄糖、硫酸软骨素与胶原蛋白治疗骨关节炎的研究进展", 《慢性病学杂志》 * |
周达岸: "中西医结合保守治疗膝关节骨性关节炎115例", 《辽宁中医药大学学报》 * |
王本龙: "《实用骨科疾病诊疗要点》", 31 March 2019, 长春:吉林科学技术出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113230381A (zh) * | 2021-06-01 | 2021-08-10 | 杭州丽昌农业科技有限公司 | 一种增加骨密度的配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101391088B (zh) | 肠胃炎口服药物 | |
CN102512630B (zh) | 一种治疗胆囊结石的中药组合物 | |
CN106266463B (zh) | 一种用于治疗高尿酸血症的中药组合物及其应用 | |
CN100522216C (zh) | 治疗跌打损伤的药物 | |
CN112402584A (zh) | 一种用于治疗骨关节炎的中西药复方药物及其制备方法 | |
CN104383403B (zh) | 一种治疗慢性胃炎的中药组合物 | |
CN102145099A (zh) | 治疗肝郁不孕的中药 | |
CN106362066A (zh) | 一种治疗风湿类风湿性疾病的药酒及其制备方法 | |
CN105687444A (zh) | 一种治疗风湿病的中药组合物及其制备方法和用途 | |
CN101129925A (zh) | 一种治疗乳腺增生症的中药制剂 | |
CN101028421B (zh) | 一种治疗慢性肾衰的中成药 | |
CN1277571C (zh) | 一种治疗胃疾的中药 | |
CN102008665A (zh) | 治疗盗汗症的中药 | |
CN105617161A (zh) | 治疗痛风的中药组合物 | |
CN1106848C (zh) | 一种治疗腰椎疾病的药物及其制备方法 | |
CN106860646B (zh) | 一种用于治疗胃十二指肠溃疡的中药组合物及其制备方法 | |
CN101085318A (zh) | 一种治疗肾病综合征的中药 | |
CN105012676A (zh) | 一种治疗小儿食欲不振的中药 | |
CN113171431A (zh) | 一种治疗类风湿的胶囊及其制备方法 | |
CN104984162A (zh) | 一种具有祛湿通络功效的中药制剂 | |
CN1263499C (zh) | 一种治疗癌症的中药 | |
CN104306585A (zh) | 一种用于治疗前列腺炎的中药组合物及其制备方法与应用 | |
CN118304369A (zh) | 一种治疗痰浊阻滞型高尿酸血症的中药组合物 | |
CN104771528A (zh) | 一种治疗尿路结石的中药组合物 | |
CN113425816A (zh) | 一种通乳的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210226 |